KRAS and pancreatic neoplasm: As LAMTOR3‐guided ERK and AKT are both important downstream signal pathways of K‐Ras, the oncogenic mutation is present in 90% of pancreatic neoplasms, as well as a research hot spot of drug therapeutic target.36, 37